Theravance Biopharma Share Price (NASDAQ: TBPH)

$13.76

▲

-0.15

(-1.08%)

Live

Last updated on August 26, 2025 at 12:37 AM IST

$₹

Check the interactive Theravance Biopharma Stock chart to analyse performance

Theravance Biopharma stock performance

as on August 26, 2025 at 12:37 AM IST

Today's Low:$13.75
Today's High:$14.26
$13.76
0.07%
Downside
Day's Volatility :3.58%
Upside
3.51%
52 Weeks Low:$7.88
52 Weeks High:$14.30
$13.76
42.73%
Downside
52 Weeks Volatility :44.9%
Upside
3.78%

Theravance Biopharma Stock Returns

Period	Theravance Biopharma Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	49.89%	6.0%	0.0%
6 Months	57.0%	-7.2%	0.0%
1 Year	70.88%	-11.1%	0.0%
3 Years	53.7%	5.5%	-10.0%

Theravance Biopharma Inc Key Stats

Check Theravance Biopharma key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$13.91
Open	$13.76
Today's High	$14.26
Today's Low	$13.63
Market Capitalization	$700.5M
Today's Volume	$846.1K
52 Week High	$14.3
52 Week Low	$7.88
Revenue TTM	$77.2M
EBITDA	$-34.0M
Earnings Per Share (EPS)	$0.24
PE Ratio	57.96
Profit Margin	16.88%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	6.23%

Stock Returns calculator for Theravance Biopharma Stock including INR - Dollar returns

The Theravance Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Theravance Biopharma investment value today

Current value as on today

₹1,73,377

Returns

₹73,377

(+73.38%)

Returns from Theravance Biopharma Stock

₹69,042 (+69.04%)

Dollar Returns*

₹4,335 (+4.33%)

Indian investors sentiment towards Theravance Biopharma Stock

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Theravance Biopharma Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Theravance Biopharma Inc

Name
Holdings %
Name
Holdings %
Madison Avenue Partners, LP
18.89%
Weiss Asset Management LP
14.81%
Newtyn Management LLC
9.83%
BlackRock Inc
6.85%
Irenic Capital Management LP
5.48%
Vanguard Group Inc
4.28%

Analyst Recommendation on Theravance Biopharma Stock

Rating

Trend

Buy

72%Buy

27%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Theravance Biopharma(by analysts ranked 0 to 5 stars)

Theravance Biopharma Share Price Target

What analysts predicted

Upside of 33.72%

Target:

$18.40

Current:

$13.76

Theravance Biopharma share price target is $18.40, a slight Upside of 33.72% compared to current price of $13.76 as per analysts' prediction.

Theravance Biopharma Stock Insights

Price Movement
In the last 1 month, TBPH stock has moved up by 26.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 15.38M → 26.19M (in $), with an average increase of 41.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -15.52M → 54.83M (in $), with an average increase of 69.6% per quarter
TBPH vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 63.2%

Theravance Biopharma Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$73.4M	↑ 21.61%
Net Income	$-236.5M	↑ 9.71%
Net Profit Margin	-322.08%	↑ 34.93%

	FY20	Y/Y Change
Revenue	$71.9M	↓ 2.12%
Net Income	$-278.0M	↑ 17.58%
Net Profit Margin	-386.9%	↓ 64.82%

	FY21	Y/Y Change
Revenue	$55.3M	↓ 23.03%
Net Income	$-199.4M	↓ 28.27%
Net Profit Margin	-360.55%	↑ 26.35%

	FY22	Y/Y Change
Revenue	$51.3M	↓ 7.17%
Net Income	$-92.8M	↓ 53.45%
Net Profit Margin	-180.78%	↑ 179.77%

	FY23	Y/Y Change
Revenue	$57.4M	↑ 11.84%
Net Income	$-55.2M	↓ 40.54%
Net Profit Margin	-96.11%	↑ 84.67%

	FY24	Y/Y Change
Revenue	$64.4M	↑ 12.12%
Net Income	$-56.4M	↑ 2.22%
Net Profit Margin	-87.63%	↑ 8.48%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$14.5M	↓ 17.43%
Net Income	$-11.7M	↑ 37.05%
Net Profit Margin	-80.42%	↓ 31.97%

	Q2 FY24	Q/Q Change
Revenue	$14.3M	↓ 1.7%
Net Income	$-16.5M	↑ 41.71%
Net Profit Margin	-115.94%	↓ 35.52%

	Q3 FY24	Q/Q Change
Revenue	$16.9M	↑ 18.32%
Net Income	$-12.7M	↓ 23.18%
Net Profit Margin	-75.28%	↑ 40.66%

	Q4 FY24	Q/Q Change
Revenue	$18.8M	↑ 11.18%
Net Income	$-15.5M	↑ 22.28%
Net Profit Margin	-82.79%	↓ 7.51%

	Q1 FY25	Q/Q Change
Revenue	$15.4M	↓ 17.95%
Net Income	$-13.6M	↓ 12.55%
Net Profit Margin	-88.24%	↓ 5.45%

	Q2 FY25	Q/Q Change
Revenue	$26.2M	↑ 70.23%
Net Income	$54.8M	↓ 503.82%
Net Profit Margin	209.33%	↑ 297.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-145.8M	↓ 344.46%

	FY20	Y/Y Change
Profit	$-189.1M	↑ 29.67%

	FY21	Y/Y Change
Profit	$48.0M	↓ 125.4%

	FY22	Y/Y Change
Profit	$44.8M	↓ 6.8%

	FY23	Y/Y Change
Profit	$57.4M	↑ 28.3%

	FY24	Y/Y Change
Profit	$64.4M	↑ 12.12%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$14.5M	↑ 9.61%

	Q2 FY24	Q/Q Change
Profit	$14.3M	↓ 1.7%

	Q3 FY24	Q/Q Change
Profit	$16.9M	↑ 18.32%

	Q4 FY24	Q/Q Change
Profit	$18.8M	↑ 11.18%

	Q1 FY25	Q/Q Change
Profit	$15.4M	↓ 17.95%

	Q2 FY25	Q/Q Change
Profit	$26.2M	↑ 70.23%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-238.2M	↑ 111.04%
Investing Cash Flow	$-83.1M	↓ 147.0%
Financing Cash Flow	$1.3M	↓ 99.43%

	FY20	Y/Y Change
Operating Cash Flow	$-250.4M	↑ 5.12%
Investing Cash Flow	$10.7M	↓ 112.91%
Financing Cash Flow	$263.1M	↑ 20278.39%

	FY21	Y/Y Change
Operating Cash Flow	$-207.9M	↓ 16.99%
Investing Cash Flow	$124.5M	↑ 1061.22%
Financing Cash Flow	$91.9M	↓ 65.08%

	FY22	Y/Y Change
Operating Cash Flow	$-187.0M	↓ 10.04%
Investing Cash Flow	$1.2B	↑ 826.96%
Financing Cash Flow	$-758.8M	↓ 926.05%

	FY23	Y/Y Change
Operating Cash Flow	$-27.0M	↓ 85.56%
Investing Cash Flow	$-32.7M	↓ 102.83%
Financing Cash Flow	$-198.9M	↓ 73.78%

	FY24	Y/Y Change
Operating Cash Flow	$-11.5M	↓ 57.27%
Investing Cash Flow	$12.3M	↓ 137.57%
Financing Cash Flow	$-2.5M	↓ 98.74%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-1.0M	↑ 19.67%
Investing Cash Flow	$17.0M	↓ 2615.21%
Financing Cash Flow	$-1.7M	↓ 94.39%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.4M	↑ 332.0%
Investing Cash Flow	$-3.0M	↓ 117.8%
Financing Cash Flow	$-44.0K	↓ 97.44%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-5.2M	↑ 17.69%
Investing Cash Flow	$-17.4M	↑ 474.03%
Financing Cash Flow	$-372.0K	↑ 745.45%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-902.0K	↓ 82.64%
Investing Cash Flow	$15.7M	↓ 190.15%
Financing Cash Flow	$-365.0K	↓ 1.88%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$43.0M	↓ 4871.51%
Investing Cash Flow	$30.6M	↑ 95.28%
Financing Cash Flow	$-854.0K	↑ 133.97%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$208.1M	↑ 383.45%
Investing Cash Flow	$-36.3M	↓ 218.37%
Financing Cash Flow	$-503.0K	↓ 41.1%

Theravance Biopharma Technicals Summary

Sell

Neutral

Buy

Theravance Biopharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Theravance Biopharma Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Theravance Biopharma Inc	25.77%	57.0%	70.88%	53.7%	-21.63%
Regeneron Pharmaceuticals, Inc.	5.52%	-17.35%	-50.85%	-1.12%	-3.68%
Beone Medicines Ltd	6.51%	21.35%	57.45%	73.21%	25.84%
Vertex Pharmaceuticals Incorporated	-14.26%	-17.97%	-18.13%	40.27%	45.64%
Alnylam Pharmaceuticals, Inc.	39.9%	82.53%	68.83%	115.41%	241.51%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Theravance Biopharma Inc	57.96	57.96	-0.05	-0.15	0.06	-0.06	NA	4.47
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.08	28.08	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Theravance Biopharma Inc	Buy	$700.5M	-21.63%	57.96	16.88%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-3.68%	14.86	31.37%
Beone Medicines Ltd	NA	$38.3B	25.84%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.3B	45.64%	28.08	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.6B	241.51%	NA	-12.96%

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Organization	Theravance Biopharma
Employees	97
CEO	Mr. Rick E. Winningham M.B.A.
Industry	Health Technology

Key Management of Theravance Biopharma Inc

Name	Title
Mr. Rick E. Winningham M.B.A.	CEO & Director
Mr. Aziz Sawaf C.F.A.	Senior VP & CFO
Mr. Brett A. Grimaud Esq.	Senior VP, General Counsel & Secretary
Mr. Stuart Knight	Senior VP of IT&I and Chief Information Officer
Ms. Rhonda F. Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs
Ms. Stacy L. Pryce	Senior VP & Chief Strategy Officer
Dr. Aine Miller Ph.D.	Senior VP of Development & Head of Ireland Office

Important FAQs about investing in TBPH Stock from India :

What is Theravance Biopharma share price today?

Theravance Biopharma share price today is $13.76 as on August 26, 2025 at 12:37 AM IST. Theravance Biopharma share today touched a day high of $14.26 and a low of $13.75.

What is the 52 week high and 52 week low for Theravance Biopharma share?

Theravance Biopharma share touched a 52 week high of $14.30 and a 52 week low of $7.88. Theravance Biopharma stock price today i.e. August 26, 2025 at 12:37 AM IST is trending at $13.76, lower by 3.78% versus the 52 week high.

How to invest in Theravance Biopharma Stock (TBPH) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Theravance Biopharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Theravance Biopharma Shares that will get you 0.1090 shares as per Theravance Biopharma share price of $13.76 per share as on August 26, 2025 at 12:37 AM IST.

What is the minimum amount required to buy Theravance Biopharma Stock (TBPH) from India?

Indian investors can start investing in Theravance Biopharma (TBPH) shares with as little as ₹87.537 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.37 in Theravance Biopharma stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Theravance Biopharma share’s latest price of $13.76 as on August 26, 2025 at 12:37 AM IST, you will get 0.7267 shares of Theravance Biopharma. Learn more about fractional shares .

What are the returns that Theravance Biopharma has given to Indian investors in the last 5 years?

Theravance Biopharma stock has given -21.63% share price returns and 18.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Global X S&p 500 Tail Risk Etf
$29.08
-0.27%
Rareview Total Return Bond Etf
$24.99
-0.24%
S&p Pharmaceuticals Spdr Etf
$46.93
-0.82%
Cambria Value And Momentum Etf
$32.25
+0.31%
Invesco Bs 2033 Hycb Etf
$25.36
+0.0%
Ishares Msci Peru And Global Exposure Etf
$53.33
+0.19%
Ishares Intl Div Growth Etf
$79.29
-0.74%
Lg Qraft Ai-powered Us Large Cap Core Etf
$37.81
-0.45%
Above Food Ingredients Inc Wt Exp 062829
$0.20
+5.26%

Explore all

Theravance Biopharma Share Price (NASDAQ: TBPH)

Theravance Biopharma stock performance

Theravance Biopharma Stock Returns

Theravance Biopharma Inc Key Stats

Stock Returns calculator for Theravance Biopharma Stock including INR - Dollar returns

Indian investors sentiment towards Theravance Biopharma Stock

Global Institutional Holdings in Theravance Biopharma Inc

Analyst Recommendation on Theravance Biopharma Stock

Theravance Biopharma Share Price Target

Theravance Biopharma Stock Insights

Price Movement

Increasing Revenue

Increasing Net Profit

TBPH vs ALNY (3 yr)

Theravance Biopharma Inc Financials

Theravance Biopharma Technicals Summary

Theravance Biopharma Inc Vs Peers

About Theravance Biopharma Inc

Key Management of Theravance Biopharma Inc

Important FAQs about investing in TBPH Stock from India :

What is Theravance Biopharma share price today?

What is the 52 week high and 52 week low for Theravance Biopharma share?

How to invest in Theravance Biopharma Stock (TBPH) from India?

What is the minimum amount required to buy Theravance Biopharma Stock (TBPH) from India?

What are the returns that Theravance Biopharma has given to Indian investors in the last 5 years?

Discover More